Celularity Inc. Class A Company Profile
NASDAQ: CELUHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Celularity at a glance
Celularity Inc. Class A (NASDAQ: CELU) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Florham Park, NJ. Celularity is led by Dr. Robert Joseph Hariri M.D., Ph.D. and employs about 115 people. The company's shares have traded publicly since 2019.
At a market capitalization of $15.2 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001752828, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Celularity do?
Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating multiple sclerosis, rheumatoid arthritis, stroke, and diabetic peripheral neuropathy. The company also produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
Business description based on the company's public filings.
Company information
- Legal name
- Celularity Inc. Class A
- Ticker
- NASDAQ: CELU
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Robert Joseph Hariri M.D., Ph.D.
- Employees
- 115
- Headquarters
- 170 Park Avenue, Florham Park, NJ, United States
- Phone
- 908 768 2170
- Website
- celularity.com
- IPO year
- 2019
- Market cap
- $15.18M
- SEC CIK
- 0001752828
- Latest annual report
- 10-K/A · Oct 20, 2026
Companies similar to Celularity
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CNTXContext Therapeutics Inc. | 0.16 | -5.10% | $14.70M | vs CELU |
| NCELNewcelX Ltd. | 2.54 | -5.58% | $14.67M | vs CELU |
| QNRXQuoin Pharmaceuticals Ltd. ADR | 3.28 | -2.35% | $15.76M | vs CELU |
| PBMPsyence Biomedical Ltd. | 2.97 | +3.85% | $15.80M | vs CELU |
| ATOSAtossa Therapeutics Inc. | 1.60 | -8.86% | $15.92M | vs CELU |
| LPCNLipocine Inc. | 1.48 | -1.33% | $16.39M | vs CELU |
| CTXRCitius Pharmaceuticals Inc. | 0.5085 | +2.27% | $13.96M | vs CELU |
| SHPHShuttle Pharmaceuticals Holdings Inc. | 3.49 | -10.51% | $16.63M | vs CELU |